Similar articles

• [Diabetes and Nephropathy: ACE inhibitor for type 1, AT1 blocker for type 2].

  Zidek W. Zidek W. MMW Fortschr Med. 2004 Oct 14;146(42):51-2. MMW Fortschr Med. 2004. PMID: 15536706 German. No abstract available.
• Reduction of proteinuria with angiotensin receptor blockers.

  Galle J. Galle J. Nat Clin Pract Cardiovasc Med. 2008 Jul;5 Suppl 1:S36-43. doi: 10.1038/ncpcardio0806. Nat Clin Pract Cardiovasc Med. 2008. PMID: 18580865 Review.
• [In the framework of the 72nd Annual Meeting of the DKG (German CardiologySociety) in Mannheim presented: Ontarget-the until now largest study program on cardiovascular prevention in patients with hypertension].

  [No authors listed] [No authors listed] MMW Fortschr Med. 2006 Jun 29;148(26):50-1. MMW Fortschr Med. 2006. PMID: 16875381 German. No abstract available.
• Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.

  Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J; Diabetics Exposed to Telmisartan and Enalapril Study Group. Barnett AH, et al. N Engl J Med. 2004 Nov 4;351(19):1952-61. doi: 10.1056/NEJMoa042274. Epub 2004 Oct 31. N Engl J Med. 2004. PMID: 15516696 Clinical Trial.
• Preventing renal complications in diabetic patients: the Diabetics Exposed to Telmisartan And enalaprIL (DETAIL) study.

  Barnett AH. Barnett AH. Acta Diabetol. 2005 Apr;42 Suppl 1:S42-9. doi: 10.1007/s00592-005-0180-4. Acta Diabetol. 2005. PMID: 15868119 Review.